All In Biotech

Drug Trial Radar · NCT07562022

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

A Phase 3 Randomized, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide Versus Rituximab and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

93

Planned (sponsor's estimate)

Start

Jun 9, 2026

Primary completion

May 2028

Study completion Jun 2029

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
First posted
May 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular lymphoma (FL).

Conditions

  • Follicular Lymphoma (FL)

Interventions

  • SCTB35 injectionDrug

    SCTB35 will be subcutaneously administered at a dose as specified

  • RituximabDrug

    Intravenous Infusion

  • LenalidomideDrug

    Oral Capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: Up to approximately 3 years
  2. Progression free survival (PFS)Time frame: Up to approximately 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.